New drug targets for Mycobacterium tuberculosis

Indian Journal of Medical Research

Volumn 117, Issue JAN., 2003, Pages 1-9

  Chopra, Puneet ^a   Meena, L S ^a   Singh, Yogendra ^a  

^a CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

Author keywords

Dormancy; Drugs; Kinases; Mycobacterium tuberculosis; Phosphatases

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ARABINOGALACTAN; BCG VACCINE; CAPREOMYCIN; CERULENIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GENISTEIN; ISONIAZID; ISOQUINOLINE INHIBITOR; K 252A; KANAMYCIN; OCTANESULPHONYL ACETAMIDE; PHOSPHATASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STAUROSPORINE; STREPTOMYCIN; THIOACETAZONE; THIOLACTOMYCIN; TRANSCRIPTION FACTOR; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BACTERIAL CELL WALL; BACTERIAL GENE; BACTERIAL GENOME; BACTERIAL METABOLISM; BACTERIAL VIRULENCE; CLINICAL TRIAL; DORMANCY; DOSE RESPONSE; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SYNTHESIS; DRUG TARGETING; ENZYME PHOSPHORYLATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENESIS; PATIENT COMPLIANCE; PROTEIN DEPHOSPHORYLATION; PROTEOMICS; REVIEW; SEQUENCE ANALYSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SUPERINFECTION; TUBERCULOSIS;

ANIMALS; GENOME; HUMANS; MYCOBACTERIUM TUBERCULOSIS; SIGNAL TRANSDUCTION; TECHNOLOGY, PHARMACEUTICAL; TRANSCRIPTION FACTORS; TUBERCULOSIS; VIRULENCE;

EID: 0037678667     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the World's slow stain: Strategies to beat multidrug-resistant tuberculosis. Science 2002; 295: 2042-6.
2. Kochi A. WHO Global Tuberculosis Programme TB: Groups at risk. WHO Report on the Tuberculosis Epidemic. Geneva: World Health Organization; 1996.
3. Culliton BJ. Drug-resistant TB may bring epidemic. Nature 1992; 356: 473.
4. Butler D. New fronts in an old war. Nature 2000; 406: 670-2.
5. Armstrong JA, Hart PD. Phagosome-lysosome interaction in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual non-fusion pattern and observations on bacterial survival. J Exp Med 1975; 142: 1-16.
6. Sturgill-Koszycki S, Schlesinger PH, Chakraborty P, Haddix PL, Collins HL, Fok AK, et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science 1994; 263; 678-81.
7. Ferrari G, Langen H, Naito M, Pieters J. A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell 1999; 97: 435-47.
8. Ramakrishnan L, Federspiel NA, Falkow S. Granuloma-specific expression of mycobacterium virulence proteins from the glycine-rich PE-PGRS family. Science 2000; 288: 1436-9.
9. World Health Organization (WHO). Tuberculosis. Fact Sheet. No. 104; Geneva: WHO; 2000.
10. Winder FG, Collins PB. Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis. J Gen Microbiol 1970; 63: 41-8.
11. Garvin RT, Biswas DK, Gorini L. The effects of streptomycin or dihydrostreptomycin binding to 16S RNA or to 30S ribosomal subunits. Proc Natl Acad Sci USA 1974; 71: 3814-8.
12. Takayama K, Kilburn JO. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother 1989; 33: 1493-9.
13. Zhang Y, Telenti A. In: Hatfull GF, Jacobs WR Jr, editors. Molecular Genetics of Mycobacteria. Washington DC: ASM Press; 2000 p. 235-54.
14. Rando RR. On the mechanism of action of antibiotics which act as irreversible enzyme inhibitors. Biochem Pharmacol 1975; 24: 1153-60.
15. Kimerling ME, Kluge H, Vezhnina N, Iacovazzi T, Demeulenaere T, Portaels F, et al. Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: Treatment failure and MDR-TB. Int J Tuberc Lung Dis 1999; 3: 451-3.
16. Zhang Y, Permer S, Sun Z. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 2002; 51: 42-9.
17. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 537-44.
18. McKinney JD, Honer Zu Bentrup K, Munoz-Elias EJ, Miczak A, Chen B, Chan WT, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000; 406: 735-8.
19. Glickman MS, Cox JS, Jacobs WR Jr. A novel mycolic acid cyclopropane synthetase is required for cording, persistence and virulence of Mycobacterium tuberculosis. Mol Cell 2000; 5: 717-27.
20. Glickman MS, Jacobs WB Jr. Microbial pathogenesis of Mycobacterium tuberculosis dawn of a discipline. Cell 2001; 104: 477-85.
21. Devergne O, Emilie D, Peuchmaur M, Crevon MC, DiAgay MF, Galanaud P. Production of cytokines in sarcoid lymph nodes: Preferential expression of interleukin-1 beta and interferon-gamma genes. Hum Pathol 1992; 23: 317-23.
22. Schuller-Levis GB, Levis WR, Ammazzalorso M, Nosrati A, Park E. Mycobacterial lipoarabinomannan induces nitric oxide and tumor necrosis factor alpha production in a macrophage cell line: Down regulation by taurine chloramine. Infect Immun 1994; 62: 4671-4.
23. Ma Y, Stern RJ, Scherman MS, Vissa VD, Yan W, Jones VC, et al. Drug targeting Mycobacterium tuberculosis cell wall synthesis: Genetics of dTDP-rhamnose synthetic enzymes and development of a microtiter plate-based screen for inhibitors of conversion of dTDP-glucose to dTDP-rhamnose. Antimicrob Agents Chemother 2001; 45: 1407-16.
24. Slayden RA, Lee RE, Armour JW, Cooper AM, Orme IM, Brennan PJ, et al. Antimycobacterial action of thiolactomycin: An inhibitor of fatty acid and mycolic acid synthesis. Antimicrob Agents Chemother 1996; 40: 2813-19.
25. Zhang Y, Amzel LM. Tuberculosis drug targets. Curr Drug Targets 2002; 3: 131-154.
26. Parrish NM, Kuhajda FP, Heine HS, Bishai WR, Dick JD. Antimycobacterial activity of cerulenin and its effects on lipid biosynthesis. J Antimicrob Chemother 1999; 43: 219-26.
27. Jones PB, Parrish NM, Houston TA, Stapon A, Bansal NP, Dick JD, et al. A new class of antituberculosis agents. J Med Chem 2000; 43: 3304-14.
28. Parrish NM, Houston T, Jones PB, Townsend C, Dick JD. In vitro activity of a novel antimycobacterial compound, N-octanesulfonylacetamide, and its effects on lipid and mycolic acid synthesis. Antimicrob Agents Chemother 2001; 45: 1143-50.
29. Berthet FX, Lagranderie M, Gounon P, Laurent-Winter C, Ensergueix D, Chavarot P, et al. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science 1998; 282: 759-62.
30. Cox JS, Chen B, McNeil M, Jacobs WR Jr. Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice. Nature 1999; 402: 79-83.
31. Alksne LE, Projan SJ. Bacterial virulence as a target for antimicrobial chemotherapy. Curr Opin Biotechnol 2000; 11: 625-36.
32. Av-Gay Y, Everett M. The eukaryotic-like Ser/Thr protein kinases of Mycobacterium tuberculosis. Trends Microbiol 2000; 8: 238-44.
33. Maiti D, Bhattacharya A, Basu J. Lipoarabinomannan from Mycobacterium tuberculosis promotes macrophage survival by phosphorylating Bad through a phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem 2001; 276: 329-33.
34. Chow K, Ng D, Stokes R, Johnson P. Protein tyrosine phosphorylation in Mycobacterium tuberculosis. FEMS Microbiol Lett 1994; 124: 203-7.
35. Hakansson S, Galyov EE, Rosqvist R, Wolf-Watz H. The Yersinia YpkA Ser/Thr kinase is translocated and subsequently targeted to the inner surface of the HeLa cell plasma membrane. Mol Microbiol 1996; 20: 593-603.
36. Tang P, Rosenshine I, Finlay BB. Listeria monocytogenes, an invasive bacterium stimulates MAP kinase upon attachment to epithelial cells. Mol Biol Cell 1994; 5: 455-64.
37. Segal ED, Lange C, Covacci A, Tompkins LS, Falkow S. Induction of host signal transduction pathways by Helicobacter pylori. Proc Natl Acad Sci USA 1997; 94: 7595-9.
38. Koul A, Choidas A, Tyagi AK, Drlica K, Singh Y, Ullrich A. Serine/threonine protein kinases PknF and PknG of Mycobacterium tuberculosis: Characterization and localization. Microbiology 2001; 147: 2307-14.
39. Chaba R, Raje M, Chakraborti PK. Evidence that a eukaryotic-type serine/threonine protein kinase from Mycobacterium tuberculosis regulates morphological changes associated with cell division. Eur J Biochem 2002; 269: 1078-85.
40. Jain R, Inouye S. Inhibition of development of Myxococcus xanthus by eukaryotic protein kinase inhibitors. J Bacteriol 1998; 180: 6544-50.
41. Drews SJ, Hung F, Av-Gay Y. A protein kinase inhibitor as an antimycobacterial agent. FEMS Microbiol Lett 2001; 205: 369-74.
42. Bliska JB, Guan K, Dixon JE, Falkow S. Tyrosine phosphate hydrolysis of host proteins by an essential Yersinia virulence determinant. Proc Natl Acad Sci USA 1991; 88 : 1187-91.
43. Fallman M, Anderson K, Hakansson S, Magnusson KE, Stendahl O, Wolf-Watz H. Yersinia pseudotuberculosis inhibits Fc receptor-mediated phagocytosis in J774 cells. Infect Immun 1995; 63: 3117-24.
44. Bliska JB, Black DS. Inhibition of the Fc receptor-mediated oxidative burst in macrophages by the Yersinia pseudotuberculosis tyrosine phosphatase. Infect Immun 1995; 63 : 681-5.
45. Fu Y, Galan JE. A Salmonella protein antagonizes Rac-1 and Cdc42 to mediate host-cell recovery after bacterial invasion. Nature 1999; 401 : 293-7.
46. Kusner DJ, Hall CF, Schlesinger LS. Activation of phospholipase D is tightly coupled to the phagocytosis of Mycobacterium tuberculosis or opsonized zymosan by human macrophages. J Exp Med 1996; 184; 585-95.
47. De Camilli P, Emr SD, Mcpherson PS, Novick P. Phosphoinositides as regulators in membrane traffic. Science 1996; 271: 1533-9.
48. Koul A, Choidas A, Treder M, Tyagi AK, Drlica K, Singh Y, et al. Cloning and characterization of secretory tyrosine phosphatases of Mycobacterium tuberculosis. J Bacteriol 2000; 182 : 5425-32.
49. Hoch JA. Two-component and phosphorelay signal transduction. Curr Opin Microbiol 2000; 3 : 165-70.
50. Zahrt TC, Deretic V. An essential two-component signal transduction system in Mycobacterium tuberculosis. J Bacteriol 2000; 182; 3832-8.
51. Dasgupta N, Kapur V, Singh KK, Das TK, Sachdeva S, Jyothisri K, et al. Characterization of a two-component system devR-devS, of Mycobacterium tuberculosis. Tuber Lung Dis 2000; 80 : 141-59.
52. Perez E, Samper S, Bordas Y, Guilhot C, Gicquel B, Martin C. An essential role for phoP in Mycobacterium tuberculosis virulence. Mol Microbiol 2001; 41 : 179-87.
53. Collins DM, Kawakami RP, De Lisle GW, Pascopella L, Bloom BR, Jacobs WR Jr. Mutation of the principal sigma factor causes loss of virulence in a strain of the Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA 1995; 92 : 8036-40.
54. Doukhan L, Predich M, Nair G, Dussurget O, Mandic-Mulec I, Cole ST, et al. Genomic organization of the mycobacterial sigma gene cluster. Gene 1995; 165 : 67-70.
55. Wu QL, Kong D, Lam K, Husson RN. A mycobacterial extracytoplasmic function sigma factor involved in survival following stress. J Bacteriol 1997; 179 : 2922-9.
56. Raman S, Song T, Puyang X, Bardarov S, Jacobs WR Jr, Husson RN. The alternative sigma factor SigH regulates major components of oxidative and heat stress responses in Mycobacterium tuberculosis. J Bacteriol 2001; 183 : 6119-25.
57. Chen P, Ruiz RE, Li Q, Silver RF, Bishai WR. Construction and characterization of a Mycobacterium tuberculosis mutant lacking the alternate sigma factor gene, sigF. Infect Immun 2000; 68 : 5575-80.
58. Buchmeier N, Blanc-Potard A, Ehrt S, Piddington D, Riley L, Groisman EA. A parallel intraphagosomal survival strategy shared by Mycobacterium tuberculosis and Salmonella enterica. Mol Microbiol 2000; 35 : 1375-82.
59. De Voss JJ, Rutter K, Schroeder BG, Su H, Zhu Y, Barry EC III. The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages. Proc Natl Acad Sci USA 2000; 97 : 1252-7.